Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
5 Results Found
AHA, others file amicus briefs opposing major drug companies’ 340B rebate models
The AHA has filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject drug companies’ proposed 340B rebate models in separate lawsuits brought by a number of drug companies to bar the agency from doing so.
HRSA directs Sanofi to cease implementing unapproved 340B rebate proposal
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA of its plans no later than Dec. 20 in order to provide adequate notice to covered entities.
HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model
Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto.
AHA, others file briefs in Maryland, West Virginia to prevent injunctions against 340B pricing for contract pharmacy arrangements
The AHA, 340B Health, Maryland Hospital Association and Mid-Atlantic Association of Community Health Centers July 9 filed an amicus brief in a federal district court in Maryland, defending the state’s law protecting 340B pricing for contract pharmacy arrangements.
AHA, others file amicus brief in Maryland to prevent injunction against 340B pricing for contract pharmacy arrangements
The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal district court in Maryland, defending the state's law protecting 340B pricing for contract pharmacy arrangements.